Singhal sees significant opportunity for diagnositics players such as Dr Lal Path Labs, Thyrocare and SRL. Organised players are already gaining market share and companies which maintain quality standards will definitely do well, he says.
first published: Aug 22, 2016 09:24 am
A collection of the most-viewed Moneycontrol videos.
Will Global Cues Keep Nifty Bulls On A Leash? All Eyes On Nvidia Earnings |Opening Bell Live
Nifty Tests 25,900 But Stages Smart Recovery From Day's Low | Closing Bell Live | 4K
The Bihar conundrum- freebies Vs Growth with NK Singh, Economist and Former MP
Will Nifty Cross 26,100 Hurdle On Weekly F&O Expiry? PhysicsWallah Lists Today|Opening Bell Live
